Skip to main content

Table 2 Clinical and demographic characteristics of the Bio-FINDER-2 cohort

From: Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer’s disease pathology

 

CU (N = 149)

MCI (N = 47)

AD (N = 63)

OND (N = 95)

Overall (N = 354)

Sex

  Female, n (%)

78 (52.3%)

20 (42.6%)

30 (47.6%)

61 (64.2%)

189 (53.4%)

  Male, n (%)

71 (47.7%)

27 (57.4%)

33 (52.4%)

34 (35.8%)

165 (46.6%)

Age, years

  Mean (SD)

64.7 (13.5)

73.1 (7.52)

74.4 (6.70)

70.5 (9.36)

69.1 (11.5)

Education, years

  Mean (SD)

12.5 (3.48)

12.5 (3.73)

11.6 (4.06)

12.2 (3.46)

12.3 (3.61)

  Missing

0 (0%)

1 (2.1%)

0 (0%)

0 (0%)

1 (0.3%)

MMSE

  Mean (SD)

29.0 (1.13)

26.6 (1.92)

19.6 (4.50)

25.5 (4.32)

26.1 (4.56)

APOEε4 carriers

  Noncarriers, n (%)

79 (53.0%)

14 (29.8%)

20 (31.7%)

61 (64.2%)

174 (49.2%)

  Carriers, n (%)

70 (47.0%)

32 (68.1%)

43 (68.3%)

34 (35.8%)

179 (50.6%)

  Missing

0 (0%)

1 (2.1%)

0 (0%)

0 (0%)

1 (0.3%)

Neocortical (18F)Flutametamol SUVR

  Mean (SD)

1.01 (0.21)

1.50 (0.29)

1.66 (0.2)

0.958 (0.08)

1.11 (0.30)

  Missing

11 (7.4%)

8 (17.0%)

59 (93.7%)

67 (70.5%)

145 (41.0%)